what-is-peptide-t-used-for The MAGE-1 protein is a key player in cancer immunology, and understanding its peptide sequences is crucial for developing targeted therapies. Specifically, the MAGE-1 protein contains various antigenic peptides that can be recognized by the immune system, particularly by cytotoxic T lymphocytes (CTLs). These peptides, often referred to as epitopes, are derived from the MAGE-1 protein and are presented on the surface of tumor cells, marking them for immune destruction. Researchers have identified several such sequences, with some being particularly well-characterized for their immunogenic properties.
The MAGE (Melanoma-Associated Antigen) family of proteins, including MAGE-1, are classified as cancer-testis antigens (CTAs). They are typically expressed in various tumor types, such as melanoma, lung carcinoma, and breast carcinoma, but are absent in normal adult tissues (with the exception of male germ cells), making them attractive targets for cancer immunotherapy. The MAGE-1 protein itself exhibits significant sequence identity with other members of the MAGE-A gene familyPepTivator MAGE-A1 is a pool of lyophilized peptides, consisting mainly of15-mer sequenceswith 11 amino acids overlap, covering the complete sequence of the ....
The identification of specific peptide sequences from MAGE-1 is a critical step in designing peptide-based vaccines or immunotherapies. These peptides, when presented by Major Histocompatibility Complex (MHC) molecules on tumor cells, can elicit a T-cell response.MAGE-A1-derived peptide acetate For instance, the peptide sequence ITKKVADLVGF, corresponding to positions 102–112 of the MAGE-1 protein, has been identified as a recognized epitope. Another example is the HLA-A1-restricted MAGE-1 peptide (161-169), which was among the first MAGE CTL epitopes mapped.
Several specific MAGE-1 peptide sequences have been described in scientific literature, often associated with particular MHC alleles, which determine their presentation to T cells.MAGE-A1-derived peptide acetateis a short peptide sequence derived from MAGE-A1 protein. As a tumor-specific antigen, MAGE-A1-derived peptide acetate can be ...
* ITKKVADLVGF: This 11-amino acid peptide is derived from positions 102–112 of the MAGE-1 protein and has been shown to be recognized by cytolytic T lymphocytes.
* MAGE-A1 (278-286), Sequence: KVLEYVIKV: This nonapeptide is another identified antigenic sequence from MAGE-A1, with a molecular weight of approximately 1090.Sequence. {Lys}{Val}{Leu}{Glu}{His}{Val}{Val}{Arg}{Val} ; Sequence Shortening, KVLEHVVRV ; Molecular Formula, C49H87N15O12 ; Molecular Weight, 1078.33 ; Length, 9.36 g/mol.
* MAGE-1 (102-112) - SESIKKKVL: This peptide sequence, while listed with slightly different positions in some sources, is also recognized and processed by tumor cells.
* MAGE-A1 (96-104): This peptide has been reported as immunogenic when administered as part of therapeutic strategies.
* H-EADPTGHSY-OH: This is a specific peptide sequence of MAGE-A1 presented by HLA-A*0101, often supplied in purified freeze-dried form.
Beyond these specific examples, MAGE-A1 can also be represented by pools of peptides, such as 15-mer sequences with overlapping amino acids that cover the complete protein sequence, offering a broader antigenic coverage.
The MAGE-1 protein and its derived peptides play a significant role in anti-tumor immunity. The expression of MAGE-1 in various cancers provides a basis for developing immunotherapies that target these antigens.Characterization of a MAGE-1-derived HLA-A24 Epitope- ... Research into these peptide sequences aims to understand how they interact with MHC molecules and T-cell receptors, facilitating the development of novel therapeutic vaccines and adoptive T-cell therapies. The ultimate goal is to leverage the immune system's ability to recognize and eliminate cancer cells expressing MAGE-1-derived peptides.
Join the newsletter to receive news, updates, new products and freebies in your inbox.